Proteomics Goes Placental

Here is an interesting news item that we’ve missed. Perkin Elmer recently announced that it will be moving forward with it’s exclusive rights to Placental Protein 13 (PP13), the “heralded” biomarker for detecting which patients may be unfortunate enough to suffer from preeclampsia. Preeclampsia has been toted as the second most frequent cause of maternal death during pregnancy. They hope to develop an assay both sensitive and specific enough to “accelerate the identification of potential treatments at the onset of the disease process and allow healthcare professionals to better manage high-risk pregnancies.” This is exciting stuff for all those who love mag-sulfate and also know when AND why to use it with pre-eclampsia.
Company website…